Novo Nordisk A/S (NVO)

$125.79

-1.29 (-1.02%)
Rating:
Recommendation:
Strong Buy
Symbol NVO
Price $125.79
Beta 0.343
Volume Avg. 1.28M
Market Cap 283.170B
Shares () -
52 Week Range 91.51-127.79
1y Target Est -
DCF Unlevered NVO DCF ->
DCF Levered NVO LDCF ->
ROE 73.26% Strong Buy
ROA 21.75% Buy
Operating Margin -
Debt / Equity 216.69% Strong Buy
P/E 43.08 Strong Buy
P/B 23.45 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NVO news


Mr. Lars Fruergaard Jrgensen
Healthcare
Biotechnology
New York Stock Exchange

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.